E10030: Clinical Trials

2 trials of E10030, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 21Completed 1

Follow E10030: new trials by email Literature Review of E10030 trials Research Report on E10030

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Ranibizumab, E10030 - Von Hippel-Lindau Syndrome
Phase 1 / Phase 2CompletedNational Eye Institute (NEI)32017-01-232021-11-01
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
E10030 - Age-related Macular Degeneration
Phase 1CompletedOphthotech Corporation182007-12-012024-02-21

Conditions studied

Macular Degeneration (1)  ·  von Hippel-Lindau Disease (1)

Sponsors

National Eye Institute (NEI) (1)  ·  Ophthotech Corporation (1)

Countries

United States (2)

Top investigators

Henry E Wiley, M.D. (1)

Results publications

PMID 34549489